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Intact β2-glycoprotein I (iβ2GPI) is a glycoprotein that regulates coagulation and ﬁbrinolysis.  Nicked 
β2GPI (nβ2GPI) possesses an angiogenic property at a relatively low concentration,  and an anti-
angiogenic property at a high concentration.  Here we investigated the functions of iβ2GPI and nβ2GPI 
in vascular endothelial growth factor (VEGF)-A-induced endothelial cell proliferation and tube forma-
tion.  We used noninvasive PET imaging to analyze the ｉｎ　ｖｉｖｏ distribution of intravenously injected 
β2GPI variants in tumor lesions in mice.  iβ2GPI was incubated with plasmin to obtain nβ2GPI,  and its 
N-terminal sequence was analyzed.  nβ2GPI had at least one other cleavage site upstream of the 
β2GPIʼs domain V,  whereas the former plasmin-cleavage site locates between K317 and T318.  Both of 
intact and nicked β2GPI signiﬁcantly inhibited the VEGF-A-induced cell proliferation and the tube 
formation of human umbilical vein endothelial cells (HUVECs).  PET imaging visualized considerably 
distributed intensities of all tested β2GPI variants in tumor lesions of pancreatic tumor cell-xenografts.  
These results indicate that β2GPI may be physiologically and pathophysiologically important in the 
regulation of not only coagulation and ﬁbrinolysis,  but also angiogenesis.
Key words:β2-glycoprotein I (β2GPI),  angiogenesis,  vascular endothelial growth factor-A (VEGF-A),  posi-
tron emission tomography (PET) imaging
β 2-Glycoprotein I (β2GPI) is a 44︲kDa phospho-lipid-binding protein that is present in normal 
human plasma at a concentration of approx.  200µg/ml 
(4µM) ﹇1﹈.  Intact β2GPI (iβ2GPI) has 5 characteris-
tic domains (DI,  DII,  DIII,  DIV,  and DV),  as so-
called “Sushi” domains.  These domains structurally 
resemble each other,  although DV has a hydrophobic 
extra C-terminal loop with a positively charged lysine/
arginine cluster that can interact with negatively 
charged substances,  such as phospholipids,  heparin,  
DNA,  platelets,  oxidized low-density lipoprotein and 
apoptotic bodies ﹇2,  3﹈.  In the 1990s,  Matsuura and 
his colleagues reported that the anticardiolipin anti-
body (aCL) associated with clinical thrombosis 
required a cofactor to bind the cardiolipin,  and the 
cofactor was identiﬁed as β2GPI,  which plays a role 
as a natural anticoagulant or pro-coagulant due to its 
ability to bind to negatively charged phospholipids 
﹇4︲6﹈.  As a major antigenic target for antiphospho-
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lipid antibodies,  β2GPIʼs pathophysiological roles in 
the ﬁelds of coagulation,  ﬁbrinolysis,  and angiogene-
sis have frequently been investigated.
　 In thrombosis,  β2GPI plays a role as an anti-
coagulant regulator.  Anti-coagulant activity is triggered 
by the binding of β2GPI to phosphatidylserine as a 
cofactor for particular reactions in the coagulation 
cascade that inhibit the generation of factor Xa from 
factor X and the generation of prothrombin to throm-
bin.  These inhibition capabilities were blocked by 
antiphospholipid antibodies (anti-β2GPI),  resulting in 
the promotion of thrombosis in antiphospholipid syn-
drome (APS) ﹇7﹈.  In ﬁbrinolysis,  domain V (DV) of 
β2GPI is frequently cleaved by plasmin between Lys︲
317 and Thr︲318 to become a nicked form of β2GPI 
(nβ2GPI),  which cannot bind to phospholipids ﹇8,  9﹈.  
nβ2GPI is known as a physiologic inhibitor of ﬁbrino-
lysis by speciﬁcally binding to plasminogen and sup-
pressing the plasmin generation ﹇10﹈.
　 Angiogenesis plays a role in both physiologic and 
pathologic states such as reproduction and embryogen-
esis,  inﬂammation and tumorigenesis,  and thrombosis 
and wound repair ﹇11,  12﹈.  Vascular endothelial growth 
factor (VEGF) signaling is required for the full exe-
cution of angiogenesis ﹇13﹈.  The major member of the 
VEGF family,  VEGF-A,  has the molecular weight 
42︲46kDa and serves as a dimer ﹇14﹈.  VEGF-A has 
higher-aﬃnity binding to VEGF receptor (VEGFR)︲1 
than VEGFR︲2,  but the level of phosphorylation of 
VEGFR︲2 in response to VEGF-A is stronger than 
that of VEGFR︲1 ﹇15﹈.
　 The role of β2GPIʼs biological functions in angio-
genesis were determined as anti-angiogenic,  as reported 
by Yu et al.  ﹇16﹈,  who also showed that β2GPI sig-
niﬁcantly inhibited VEGF- and basic ﬁbroblast growth 
factor (bFGF)-induced angiogenesis and that the inhi-
bition activity may be mediated through its DI binding.  
nβ2GPI has also been described as a potent anti-
angiogenic and anti-tumor molecule of potential thera-
peutic signiﬁcance ﹇17,  18﹈.  In contrast,  at lower 
concentrations nβ2GPI has a signiﬁcant binding 
capability to angiostatin 4.5 (AS4.5; plasmin auto-
proteolysis) that attenuates the anti-angiogenic func-
tions of AS4.5,  resulting in the promotion of angio-
genesis ﹇17﹈.
　 Treatments using targeted therapies were recently 
applied to tumors.  As angiogenesis is the key to a 
tumorʼs autonomy,  the ability to monitor the angiogen-
esis process in vivo will contribute to the management 
of such interventions.  Positron emission topography 
(PET),  which could be used for this purpose ﹇19﹈,  is 
a noninvasive molecular imaging modality that can 
characterize biological processes in tissues and organs,  
and it is used to measure the in vivo biodistribution of 
imaging agents labeled with positron-emitting radionu-
clides ﹇20﹈.
　 In the present study,  we evaluated the ability of 
iβ2GPI and nβ2GPI to inhibit VEGF-A-induced cell 
proliferation and tube formation,  using human umbili-
cal vein endothelial cells (HUVECs).  We speculated 
that β2GPI might have physiologically and/or patho-
physiologically important roles in the regulation of not 
only coagulation and ﬁbrinolysis,  but also angiogene-
sis.  We also suspected that β2GPI can distribute into 
tumor lesions,  which may prove beneﬁcial to the 
development of diagnostic and targeted therapies.
Materials and Methods
　β₂ɢＰɪ　ｖａｒｉａｎｔｓ． iβ2GPI was prepared from 
fresh normal plasma as described ﹇21﹈ and nβ2GPI 
was prepared by incubating iβ2GPI with plasmin.  In 
brief,  to obtain nβ2GPI,  recombinant human plasmin 
from Wako Pure Chemical Industries (Osaka,  Japan) 
was ﬁxed to Aﬃ-Gel 10 gels (Bio-Rad,  Osaka,  Japan) 
and incubated with iβ2GPI at 37℃ for 16h,  and then 
the supernatant was recovered.  We veriﬁed the cleav-
age by sodium dodecylsulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) on 4︲20  a Tris-HCl gel 
under non-reducing/reducing conditions,  and then we 
identiﬁed the bands by N-terminal sequencing with the 
use of a PPSQ︲33B protein sequencer (Shimadzu,  
Kyoto,  Japan).
　 ɴ︲ｔｅｒⅿｉｎａˡ　 ｓｅｑｕｅｎｃｅ　 ａｎｄ　 ＭＡʟＤɪ︲ＴＯＦ　 ＭＳ　
ａｎａˡｙｓｉｓ． The plasmin-cleavage site of iβ2GPI was 
identiﬁed by its N-terminal sequence.  Brieﬂy,  we 
separated puriﬁed intact/nicked β2GPI by SDS-
PAGE and electroblotted the protein bands onto 
Immobilon® PVDF transfer membranes (0.2µm pore 
size,  Merck Millipore,  Cork,  Ireland).  The membranes 
were stained with Coomassie Brilliant Blue,  and the 
bands of iβ2GPI and nβ2GPI were cut out and then 
destained with 60  methanol.  Sequencing was ana-
lyzed using the protein sequencer.
　 We performed AXIMA® Performance matrix 
assisted laser desorption ionization time-of-ﬂight mass 
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spectrometry (MALDI-TOF MS; Shimadzu) to con-
ﬁrm the purity and to detect the molecular weight of 
intact/nicked β2GPI.  Sinapinic acid (SA) purchased 
from Shimadzu was used as the matrix.  The MALDI-
TOF MS was performed using a positive ion source in 
reﬂectron mode.  The data were collected using 
Launch Pad 2.8 software used to control the spec-
trometer (Shimadzu).  The mass-to-charge ratio (m/z) 
was obtained by external calibration using bovine 
serum albumin (BSA) and bovine insulin (Sigma 
Aldrich,  St. Louis,  MO,  USA).
　 Ｃｅˡˡ　 ｃｕˡｔｕｒｅ． HUVECs were obtained from 
Kurabo Industries (Osaka,  Japan) and cultured in a 
moisturized chamber at 37℃ with 5  CO2,  using the 
cell-culture medium HuMedia-EG2 (Kurabo) supple-
mented with a ﬁnal concentration of 2  fetal calf 
serum (FCS),  10ng/ml human epidermal growth fac-
tor (hEGF),  5ng/ml human ﬁbroblast growth factor 
(hFGF),  10µg/ml heparin,  1.34µg/ml hydrocorti-
sone,  50ng/ml amphotericin B,  and 50µg/ml genta-
micin.  HUVECs from passages 2 to 6 were used in the 
following experiments.
　 Ｃｅˡˡ　 ｐｒｏˡｉｆｅｒａｔｉｏｎ　 ａｓｓａｙ． To observe the 
eﬀects of each β2GPI variant on the proliferation of 
HUVECs,  we performed a cell proliferation assay.  
The experiment was done using HuMedia-EG2 medium 
with hEGF reduced to a ﬁnal concentration of 5ng/ml.  
First,  5×103 HUVECs in 100µl of medium were 
seeded into the wells of a 96︲well microtiter plate,  
cultured for 24h and then serum-starved for another 
3h.  Diﬀerent concentrations of iβ2GPI and nβ2GPI 
with/without 2.5ng/ml of human recombinant VEGF-A 
(Kurabo) were added to the medium.  After a 72︲h 
incubation at 37℃,  10µl of Cell Counting Kit︲8 
(Dojindo,  Kumamoto,  Japan) was added to the wells 
and the cells were incubated for another 3.5h at 37℃.  
The optical density (OD) at 450nm was then measured.  
Triplicate assays were performed 3 times.
　 ɪｎ　ｖｉｔｒｏ　ｔｕｂｅ　ｆｏｒⅿａｔｉｏｎ． A 96︲well microtiter 
plate was coated with 50µl of Cultrex® Basement 
Membrane Extract (BME) Reduced Growth Factor 
gels (Trevigen,  Gaithersburg,  MD,  USA) and solidi-
ﬁed for 60min at 37℃.  HUVECs (1×104 per well) 
were seeded onto the surface of the gel and cultured 
in HuMedia-EG2 medium without heparin and with 
hEGF reduced to a ﬁnal concentration of 5ng/ml.  
Assays were performed according to the manufac-
turerʼs instructions (Trevigen) in the absence or pres-
ence of VEGF-A (5ng/ml) and intact/nicked β2GPI at 
the ﬁnal concentration of 0.05 to 1µM.  Sulforaphan 
was added to the culture as a potent angiogenesis 
inhibitor.  Tube length formation was monitored over 
a 6-h period and photographed with a ﬂuorescence 
microscopic imaging system (model IX71,  Olympus,  
Tokyo,  Japan; 4× magniﬁcation).  The image analysis 
of the tube length formation was carried out using 
Image J Angiogenesis Analyzer,  v1.49q software.
　 Ｅｎｚｙⅿｅ︲ˡｉｎｋｅｄ　 ｉⅿⅿｕｎｏｓｏｒｂｅｎｔ　 ａｓｓａｙ　
⎝ＥʟɪＳＡ⎠　ｆｏｒ　ʰｕⅿａｎ　ＶＥɢＦ︲Ａ． We cultured and 
maintained the pancreatic carcinoma cell lines 
CFPAC︲1 & MIA PaCa︲2 (ATCC,  Manassas,  VA,  
USA) using Iscoveʼs Modiﬁed Dulbeccoʼs Medium 
(IMDM; Gibco/Life Technologies,  Tokyo,  Japan),  
PANC︲1 (ATCC) using Dulbeccoʼs Modiﬁed Eagle 
Medium (DMEM; Gibco/Life Technologies) and 
BxPC︲3 (ATCC) using Roswell Park Memonal lnsti-
tute (RPMI)︲1640 (Gibco/Life Technologies) added 
with 10  FBS and 1  of Penicillin-Streptomycin 
Mixed Solution (Nacalai Tesque,  Kyoto,  Japan).  
Each of the 4 cell lines (1×106 cells) was seeded into 
10︲cm dishes containing the complete medium.  The 
cultured media were collected after the cell growth 
reached 80︲90  conﬂuence.  We performed an ELISA 
for human VEGF-A with collected cultured media from 
the pancreatic carcinoma cell lines as speciﬁed by the 
manufacturerʼs instructions using a human VEGF-A 
kit from R&D Systems (Minneapolis,  MN,  USA).
　 ɪｎｏｃｕˡａｔｉｎɡ　ｔｕⅿｏｒ　ｃｅˡˡｓ　ｔｏ　ⅿｉｃｅ． All animal 
experiments were supervised under Okayama University 
guidelines and in agreement with the Universityʼs 
Animal Care and Use Committee (OKU︲2013098).  
The human pancreatic cancer cell line CFPAC︲1 
(CRL︲1918TM,  ATCC) derived from liver metasta-
sis was cultured at 37℃ with 5  CO2,  using IMDM 
as described above containing 10  FBS and 1  
Penicillin-Streptomycin Mixed Solution.  The cultured 
cancer cells were harvested,  washed,  and re-sus-
pended with Matrigel using a 1 : 1 volume ratio before 
being injected into mice.
　 Five-week-old male BALB/c nu/nu mice (Charles 
River,  Tokyo,  Japan) were inoculated subcutaneously 
with CFPAC︲1 cells (3×106 cells) per mouse on the 
right shoulder.  The body weights of the mice and the 
volumes of the tumors were measured 2 weeks after 
the inoculation,  and the tumor-bearing mice were then 
prepared for PET imaging.
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　 Ｃｏｎʲｕɡａｔｉｏｎ　 ʷｉｔʰ　 ａ　 ｃʰｅˡａｔｉｎɡ　 ａɡｅｎｔ　 ａｎｄ　
ｒａｄｉｏˡａｂｅˡｉｎɡ　ｏｆ　β₂ɢＰɪ　ｖａｒｉａｎｔｓ． One-hundred 
mM EDTA (3µl) was added to iβ2GPI and nβ2GPI 
(1mg) to complex any free trace metal ion.  Both 
iβ2GPI and nβ2GPI were concentrated into 0.1M 
HEPES (pH8.9) by centrifugation in Amicon Ultra 
0.5 10K centrifugal tubes (Merck Milipore,  Tokyo,  
Japan).  Conjugation with 2︲S-(4︲isothiocyanatobenzyl)-
1,4,7︲triazacyclononane︲1,4,7︲triacetic acid (p-SCN-
Bn-NOTA: Macrocyclics,  Dallas,  TX,  USA) was 
applied to iβ2GPI,  iβ2GPI in the presence of dio-
leoylphosphatidylglycerol (DOPG) and nβ2GPI.  To 
avoid p-SCN-Bn-NOTA (NOTA) conjugation at the 
phospholipid binding region in DV,  NOTA was reacted 
to iβ2GPI in the presence of DOPG.  Brieﬂy,  DOPG 
solution in chloroform was dried in a glass tube under 
N2,  added with 0.1M HEPES buﬀer (pH8.9) and then 
sonicated. Next, iβ2GPI was mixed with DOPG micelle 
solutions with a 1 : 1 volume ratio and incubated for 
30min at room temperature to make iβ2GPI-DOPG 
complex.
　 Conjugation to the NOTA chelator was achieved as 
described with slight modiﬁcation ﹇22,  23﹈.  NOTA 
was dissolved with dimethyl sulfoxide (DMSO;  
Sigma-Aldrich) to make 22.4mg/ml solution by vortex 
and sonication.  An 80︲fold molar concentration of 
NOTA-DMSO solution was added into iβ2GPI,  the 
iβ2GPI-DOPG complex solutions and nβ2GPI,  and 
then conjugation was allowed to proceed at 37℃ for 
1h with gentle mixing.  All reaction mixtures were 
then fractionated using PD︲10 columns (Sephadex 
G︲25 M,  GE Healthcare,  Buckinghamshire,  UK) with 
phosphate-buﬀered saline (PBS) to separate the 
NOTA-conjugated variants (NOTA-iβ2GPI,  NOTA-
DOPG-iβ2GPI and NOTA-nβ2GPI) from free NOTA.  
The DOPG in the NOTA-DOPG-iβ2GPI was then 
delipidated with n-butanol.  We named the delipidated 
protein as NOTA-iβ2GPI (masked).
　 For radiolabeling,  Copper︲64 (64Cu) (239︲269MBq) 
diluted in 5mg/ml gentisic acid saline and 0.1M phos-
phate buﬀer (pH5.5) was added to 0.2mg of NOTA- 
iβ2GPI, 0.2mg of NOTA-iβ2GPI (masked), or 0.165mg 
of NOTA-conjugated nβ2GPI (NOTA-nβ2GPI),  
respectively.  All reaction mixtures were incubated at 
37℃ for 10min,  and then we used thin layer chroma-
tography and autoradiography (TLC-ARG) to conﬁrm 
the radiolabeling eﬃciency.  Brieﬂy,  each sample was 
spotted on a silica gel plate (at the original position) 
developed using 50mM EDTA (pH8.0).  The NOTA- 
β2GPI variants-bound 64Cu radioactivity stayed at the 
origin and unbound 64Cu went to the upper part of the 
chromatogram.  The reaction mixtures were then 
supplemented with 10  0.1M EDTA (pH7.0) and 
centrifuged in Amicon Ultra 0.5 10K centrifugal tubes 
to eliminate the free 64Cu.
　 ＥʟɪＳＡ　ｆｏｒ　ａｎｔｉｂｏｄｙ　ｂｉｎｄｉｎɡ． To measure the 
antibody binding ability to negatively charged lipids of 
iβ2GPI,  NOTA-iβ2GPI,  NOTA-iβ2GPI (masked) 
and nβ2GPI,  we performed an ELISA,  as previously 
described ﹇24﹈.  Fifty µg/ml of cardiolipin was immo-
bilized onto the wells of a 96︲well microtiter plate 
(Immulon IB,  Thermo Scientiﬁc,  Rochester,  NY,  
USA) and allowed to dry.  The wells were then 
blocked with PBS containing 0.2  BSA for 1h at 
room temperature and washed 3 times with 0.05  
Tween︲20 in PBS.  Serial dilutions of the sample 
solutions were added to the wells and incubated for 
1h.  After 3 washes,  the wells were treated with 
1µg/ml of Cof︲20 antibody for 1h.  The wells were 
then washed,  and antibody binding against domain III 
of β2GPI was detected by 30︲min incubation with 
peroxidase-labeled anti-mouse IgG (Life Technologies,  
Tokyo,  Japan).  After 3 washes,  color was developed 
by adding 100µl of TMB-US substrate (Moss,  
Pasadena,  MD,  USA) to the wells.  To stop the reac-
tion,  100µl of 2N H2SO4 was applied,  and then the 
OD values were measured at 450nm with a microplate 
reader (Bio-Rad 550,  Hercules,  CA,  USA).
　 ＰＥＴ　 ｉⅿａɡｉｎɡ　 ａｎｄ　 ｔｉｓｓｕｅ　 ｂｉｏｄｉｓｔｒｉｂｕｔｉｏｎ．
Each mouse bearing a CFPAC︲1 tumor was anesthe-
tized by isoﬂurane inhalation and intravenously 
injected with approx.  20MBq/20µg of 64Cu-NOTA- 
iβ2GPI (n＝3), 26MBq/20µg of 64Cu-NOTA-iβ2GPI 
(masked) (n＝3),  or 15MBq/21µg of 64Cu-NOTA- 
nβ2GPI (n＝3).  We conducted emission scans for 10 
min (at 0h),  30min (at 24h) and 60min (at 48h) using 
a small-animal PET scanner (Clairvivo PET, Shimadzu), 
and the images were reconstructed using the 
3D-DRAMA method.  At the end of the ﬁnal PET 
scans at 48h post-injection,  all mice were sacriﬁced 
for biodistribution studies.
　 In addition,  separate groups of mice (n＝3 each) 
were administered 64Cu-NOTA-iβ2GPI (20MBq),  
64Cu-NOTA-iβ2GPI (masked) (26MBq),  or 64Cu- 
NOTA-nβ2GPI (approx.  2MBq) and sacriﬁced 24h 
post-injection for biodistribution studies.  The tumors 
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and major organs of the mice were collected and 
weighed,  and we measured the radioactivity of the 
organs with a gamma-counter (AccuFLEX γ7001,  
Hitachi Aloka Medical,  Tokyo,  Japan).  The biodistri-
bution data are expressed as the percentage of the 
injected dose per gram of tissues (  ID/g).
　 Ｓｔａｔｉｓｔｉｃａˡ　 ａｎａˡｙｓｉｓ． The statistical signiﬁ-
cance of the data was evaluated by Studentʼs t-test.  
Probability values＜0.05 were considered signiﬁcant.
Results
　 Ｐｕｒｉﬁ ｃａｔｉｏｎ　ａｎｄ　ｃʰａｒａｃｔｅｒｉｚａｔｉｏｎ　ｏｆ　ｎβ₂ɢＰɪ．
iβ2GPI showed a single band by SDS-PAGE analysis 
under reducing conditions.  The SDS-PAGE analysis 
of nβ2GPI conﬁrmed that iβ2GPI was cleaved and the 
resulting band showed an interval with the band of 
iβ2GPI (Fig.  1A).  N-Terminal sequencing identiﬁed 
that iβ2GPI was cleaved by plasmin under non-reduc-
ing conditions,  and N-terminal sequences were con-
ﬁrmed (G1RT×PKPDDLPF,  T318DASDVK).  In that 
experiment,  a novel N-terminal sequence (another 
cleavage site sensitive to plasmin at the upstream in 
DV rather than T318) was also identiﬁed (data not 
shown).  Proteolytic cleavage seems to be reasonable 
to explain the MALDI-TOF MS size diﬀerence (i.e.,  
the average molecular weights of iβ2GPI and nβ2GPI 
determined by MALDI-TOF MS were 44kDa and 
38kDa,  respectively) as shown in Fig.  1B.  We are 
now testing these results using a set of recombinant 
mutant proteins of β2GPI; we will publish those data 
elsewhere.
　 Ｅﬀ ｅｃｔｓ　ｏｆ　ｔʰｅ　β₂ɢＰɪ　ｖａｒｉａｎｔｓ　ｏｎ　ｔʰｅ　ＶＥɢＦ︲
Ａ︲ｄｅｐｅｎｄｅｎｔ　 ｐｒｏˡｉｆｅｒａｔｉｏｎ　 ｏｆ　 ʜＵＶＥＣｓ． The 
growth of the HUVECs treated with VEGF-A at 
concentrations from 1.25 to 10ng/ml increased dose-
dependently (Fig.  2A).  The VEGF-A at 2.5︲10ng/ml 
signiﬁcantly increased the growth of the HUVECs.  
To observe the inhibitory eﬀect of β2GPI on VEGF-
A-induced cell growth,  we incubated HUVECs with 
intact/nicked β2GPI in the presence of 2.5ng/ml of 
VEGF-A. As shown in Fig. 2B, intact/nicked β2GPI 
decreased the VEGF-A-induced growth of the HUVECs 
in a dose-dependent manner.  Nicked β2GPI signiﬁ-
cantly suppressed the HUVECsʼ growth at the concen-
trations of 0.125,  0.5 and 1µM,  whereas iβ2GPI 
signiﬁcantly suppressed the VEGF-A-induced growth 
of the cells at the lowest to the highest concentrations 
(0.063︲1µM).  These results indicate the inhibitory 
role of iβ2GPI and nβ2GPI on VEGF-A-induced 
HUVECs cell proliferation.
　 Ｅﬀ ｅｃｔｓ　ｏｆ　ｔʰｅ　β₂ɢＰɪ　ｖａｒｉａｎｔｓ　ｏｎ　ｔʰｅ　ＶＥɢＦ︲
Ａ︲ｄｅｐｅｎｄｅｎｔ　ｔｕｂｅ　ｆｏｒⅿａｔｉｏｎ　ｏｆ　ʜＵＶＥＣｓ． To 
observe the tube formation of HUVECs and to evalu-
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Fig. 1　 Puriﬁcation of nicked β2GPI.  (A) 1,  iβ2GPI and 2,  iβ2GPI cleaved by plasmin (nβ2GPI) showed a clear band on SDS-PAGE 
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as a positive control.  (A) HUVECs were visualized by ﬂuorescence 
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Values are expressed as the percentage of the VEGF-alone control 
group set as 100%.  ＊ｐ＜0. 05,  ＊＊ｐ＜0.01 vs. VEGF-alone.
ate the inhibition of angiogenesis by each protein,  we 
conducted in vitro angiogenesis assays.  The treatment 
of the cells with iβ2GPI and nβ2GPI resulted in the 
suppression of VEGF-A-stimulated tube formation.  
Fig.  3A shows examples of the tube formation of 
untreated and/or treated HUVECs by ﬂuorescence 
microscopy.  In this assay,  higher concentrations of 
iβ2GPI and nβ2GPI suppressed the tube length for-
mation.  Signiﬁcant eﬀects on VEGF-A-dependent tube 
formation obtained by iβ2GPI and nβ2GPI were 
observed (Fig.  3B).
　 Ｅｘｐｒｅｓｓｉｏｎ　ｏｆ　ＶＥɢＦ︲Ａ　ｂｙ　ｔʰｅ　ｆｏｕｒ　ｐａｎｃｒｅ︲
ａｔｉｃ　ｃａｒｃｉｎｏⅿａ　ｃｅˡˡ　ˡｉｎｅｓ． VEGF-A was detected 
in all four of the human pancreatic carcinoma cell lines 
used in this study (Fig.  4).  Compared to the other cell 
lines,  the CFPAC︲1 cells grew relatively rapidly and 
secreted the largest amount of VEGF-A in their cul-
ture supernatant.  We therefore decided to inoculate 
the mice with CFPAC︲1 cells (xenografts) for the 
PET imaging studies.
　 Ｃｏｎʲｕɡａｔｉｏｎ　ʷｉｔʰ　ɴＯＴＡ　ａｎｄ　ｒａｄｉｏˡａｂｅˡｉｎɡ．
NOTA-iβ2GPI,  NOTA-iβ2GPI (masked) and NOTA- 
nβ2GPI were each puriﬁed by column chromatogra-
phy with PD︲10,  and then the average molecular 
weights were measured by MALDI-TOF MS.  The 
average number of NOTA molecules per iβ2GPI,  
iβ2GPI (masked) and nβ2GPI molecules were 3.8,  2.9 
and 1.3,  respectively.  These numbers were deter-
mined by dividing the mass diﬀerence between each 
NOTA-β2GPI variants and iβ2GPI or nβ2GPI by the 
molecular weight of NOTA (559.9Da).  We then deter-
mined the binding ability to solid-phase cardiolipin of 
NOTA-conjugated β2GPI by performing an ELISA to 
observe the eﬀect of NOTA conjugation.  nβ2GPI 
appeared to be unbound to cardiolipin (Fig.  5A) 
because the phospholipid binding site was cleaved by 
plasmin.  Fig.  5B shows that the binding of NOTA- 
iβ2GPI (masked) to cardiolipin was moderate com-
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Fig. 4　 Human VEGF-A ELISA.  Among the four pancreatic tumor 
cell lines tested,  the CFPAC︲1 tumor cells secreted the largest 
amount of VEGF-A as determined by a human VEGF-A ELISA.
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pared to the original iβ2GPI,  whereas the binding of 
NOTA-iβ2GPI was much lower than that of iβ2GPI.  
These results indicated that the NOTA molecule was 
conjugated to lysine residue(s) which are located 
closely or exactly on the phospholipid binding site of 
β2GPI in NOTA-iβ2GPI.  The results also indicated 
that the masking of DOPG in NOTA-iβ2GPI (masked) 
prevented the conjugation of NOTA to the site(s).
　 The radiolabeling of NOTA-conjugated β2GPI 
showed radiolabeling eﬃciency of 96.4 ,  97.1  and 
88.3  for 64Cu-NOTA-iβ2GPI,  64Cu-NOTA-iβ2GPI 
(masked) and 64Cu-NOTA-nβ2GPI,  respectively.  The 
speciﬁc activities of 64Cu-NOTA-iβ2GPI, 64Cu-NOTA- 
iβ2GPI (masked) and 64Cu-NOTA-nβ2GPI were 0.98,  
1.3 and 0.71MBq/µg at the end of puriﬁcation,  
respectively.
　 ＰＥＴ　 ｉⅿａɡｉｎɡ　 ａｎｄ　 ｂｉｏｄｉｓｔｒｉｂｕｔｉｏｎ　 ｓｔｕｄｉｅｓ．
To observe the in vivo distribution of β2GPI and its 
variants in tumor lesions,  we performed the PET 
studies.  PET imaging of 64Cu-NOTA-iβ2GPI,  64Cu- 
NOTA-iβ2GPI (masked),  and 64Cu-NOTA-nβ2GPI 
was done with tumor-bearing mice at 0,  24 and 48h 
post-injection.  Fig.  6 shows the resulting PET images.  
Considerable intensities could be observed in the 
tumor lesions at 24 and 48h.
　 Following the PET imaging studies,  all mice were 
euthanized for biodistribution studies as shown at Fig.  
7A,  B.  The intensity of each probe was greatest in 
the kidney,  the liver and  the tumor,  in that order.  
The ratios of tumor to blood and tumor to muscle 
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Fig. 6　 PET imaging.  Representative 
PET images of the tumor-bearing mice 
at 0, 24 and 48h after the injections of 
β2GPIs-labeled 64Cu.  Images show the 
maximum intensity projections (MIP) of 
whole bodies.  From top to bottom: a 
mouse injected with 64Cu-NOTA-iβ
2GPI, 64Cu-NOTA-iβ2GPI (masked) and 
64Cu-NOTA-nβ2GPI.  The upper thresh-
olds of PET images were adjusted for 
visual clarity,  as indicated by the scale 
bars.  Considerable intensities were 
observed in the kidney (red arrow), the 
liver (yellow arrow) and the tumor (white 
arrow).
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Fig. 7　 Biodistribution studies of 64Cu-NOTA-conjugated β2GPI variants.  Biodistribution of probes at (A) 24h and (B) 48h in tumor-
bearing mice after they were i.v.-injected with 64Cu-NOTA-iβ2GPI (white bars), 64Cu-NOTA-iβ2GPI (masked) (gray bars) or 64Cu-NOTA- 
nβ2GPI (black bars).  The data were calculated as the % of injected dose per gram of tissue (%ID/g).  The ratios of tumor to blood (C) and 
tumor to muscle (D) at 24 and 48h post-injection are shown.
(Fig.  7C,  D) showed the probes level to attain the 
tumor region which were normalized by the blood and 
the muscle.
Discussion
　 To determine the precise role of β2GPI in angio-
genesis－toward the development of therapeutic 
medication－we performed in vitro and in vivo experi-
ments using puriﬁed iβ2GPI and nβ2GPI.  The in vitro 
experiment was conducted because endothelial cells 
have an essential role in the process of vascular 
remodeling.  HUVECs are commonly employed for 
physiological and pharmacological investigations; e.g.,  
studies of blood coagulation,  angiogenesis and ﬁbrino-
lysis.  We used PET imaging in the present in vivo 
study to investigate the intensity level of β2GPI and 
its in vivo distribution,  because PET is noninvasive 
and is directed to the entire body.
　β2GPI was described as the major antigen for 
aCL,  which binds to anionic phospholipids ﹇3︲6﹈.  
The binding of β2GPI to phospholipid via its C-terminal 
loop was reported to be signiﬁcantly reduced by plas-
min cleavage between K317 and T318 ﹇8,  9﹈.  In this 
study,  we are surprised to discover cleavage sites in 
DV of β2GPI other than the cleavage between K317 and 
T318.  Numerous studies ﹇8,  9,  24,  25﹈ have discussed 
iβ2GPIsʼ plasmin-cleavage including the cleavage site 
at K317︲T318,  but there were few studies regarding the 
molecular weight diﬀerence between iβ2GPI and 
nβ2GPI based on SDS-PAGE gel results under non-
reducing condition.
　 The present study is the ﬁrst to use MALDI-TOF 
MS to conﬁrm the molecular weights of intact/nicked 
β2GPI,  as this is a new approach for both.  The 
MALDI-TOF MS ﬁndings clearly showed that the 
average molecular weight of nβ2GPI (38kDa) is quite 
diﬀerent from that of iβ2GPI (44kDa),  which corre-
sponds to the individual bands of iβ2GPI and nβ2GPI 
in the SDS-PAGE results.  Under reducing conditions,  
the disulﬁde (S-S) bonds will be reduced by 2︲mercap-
toethanol,  whereas nβ2GPI showed a much diﬀerent 
size compared to iβ2GPI; ＞935Da larger (from T318 
to C326).  Our results suggest that nβ2GPI has at least 
one more cleavage site upstream of β2GPIʼs domain V 
in which the former plasmin-cleavage site is located 
between K317 and T318.  Further studies are needed to 
explore the roles of nβ2GPI cleavages.
　 Several studies showed that iβ2GPI  and nβ2GPI 
have angiogenic properties that could suppress tumor 
growth by blocking the neovascularization ﹇18,  26,  
27﹈.  In the present study,  we ﬁnd that iβ2GPI inhib-
ited the VEGF-A-induced cell proliferation and 
VEGF-A-stimulated tube formation of HUVECs.  
These results do not contradict those of the Chiu et al.  
﹇28﹈ report that β2GPI suppressed VEGF-induced 
endothelial cell growth and migration.  Similar results 
regarding the cell proliferation and tube formation 
induced by VEGF-A were obtained in the present 
study by incubating HUVECs with nβ2GPI.
　 Our results are also in concurrence with those of 
Sakai et al.  ﹇18﹈ and Beecken et al.  ﹇29﹈,  who 
reported inhibitory eﬀects of nβ2GPI on endothelial 
cell proliferation in vitro and vascularization in vivo.  
Based on our ﬁndings,  we propose that intact/nicked 
β2GPI may have inhibitor property against VEGF-A-
dependent angiogenesis.  It is debatable whether 
β2GPI downregulates the VEGF-A or VEGFR︲1/
VEGFR︲2 directly.  Another investigation is required 
to clarify whether intact/nicked β2GPIsʼ role in 
angiogenesis involves direct binding to VEGF-A or 
VEGFR︲1/VEGFR︲2.
　 We used PET imaging with iβ2GPI and nβ2GPI 
to test the recent results studies indicating that intact 
and nicked β2GPI possess angiogenic properties that 
may prove beneﬁcial for the development of therapeu-
tic medicine as an angiogenesis-targeted treatment.  
The imaging study was necessary to evaluate the dis-
tribution of both proteins in tumor-bearing mice.  
Compared to other pancreatic tumor cells (MIA 
PaCa︲2 and PANC︲1),  CFPAC︲1 cells strongly 
expressed microRNA︲21 (miR︲21) which was posi-
tively correlated with the expression of mRNA of 
VEGF ﹇30﹈.  Our present experiment showed that 
CFPAC︲1 cells grew relatively rapidly and secreted 
the largest amount of VEGF-A among the 4 tumor cell 
lines examined,  and for this reason we inoculated 
CFPAC︲1 cells into mice for the PET imaging.  As a 
chelating agent for 64Cu,  we used NOTA.  Zhang et al.  
﹇31﹈ had revealed that NOTA is one of the best che-
lators for the 64Cu-labeling of proteins,  macromole-
cules or nanomaterials.
　 We prepared 3 probes to evaluate the intensity of 
each probe in CFPAC︲1 tumors by PET imaging,  
which are 64Cu-NOTA-iβ2GPI,  64Cu-NOTA-iβ2GPI 
(masked) and 64Cu-NOTA-nβ2GPI.  The binding of 
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NOTA-iβ2GPI (masked) to cardiolipin indicated that 
the aﬃnity to the cardiolipin was similar to that of the 
original iβ2GPI,  even after conjugation with NOTA 
(Fig.  5B).  We suspect that these results reﬂect the 
ability of NOTA-conjugated β2GPIs to bind cardio-
lipin.  In addition,  the masking eﬀect by DOPG at 
β2GPIsʼ phospholipid binding site inﬂuenced the aver-
age number of NOTA-conjugated molecules.
　 Even though the angiogenesis assay results sug-
gested that iβ2GPI more eﬀectively suppressed the 
VEGF-A-dependent cell proliferation compared to 
nβ2GPI,  the three probes showed similar kinetic 
eﬃciency at 24 and 48h.  In addition,  there were no 
signiﬁcant diﬀerences between them in the PET imag-
ing results.  It is possible that iβ2GPI suppressed the 
HUVEC proliferation as a result of β2GPI expression 
by the endothelial cells ﹇32﹈.
　 We observed the considerable intensities of the 
iβ2GPI variants in the tumor lesions.  A possible 
explanation of this result is that it was caused by the 
binding of β2GPI to some sort of molecule(s) such as 
VEGF-A in the tumor lesions.  However,  we are not 
able to exclude the possibility that the intensities 
observed in the tumor lesions led to the abundant 
circulating blood in the tumors,  which have rich neo-
vascular vessels.  Further investigation is needed to 
investigate the several potential binding activities of 
iβ2GPI and nβ2GPI to other molecules in the tumor 
lesions,  such as annexin II ﹇33﹈,  toll-like receptor 2 
(TLR2) ﹇34﹈,  and other receptors in tumors.
　 In conclusion,  we found that nβ2GPI has at least 
one other cleavage site upstream of the β2GPIʼs DV 
in which the former plasmin-cleavage site between K317 
and T318 is located.  Our ﬁndings also demonstrated 
iβ2GPI and nβ2GPI as angiogenesis inhibitors of 
VEGF-A-induced HUVECs cell proliferation and tube 
formation.  These results indicate that β2GPI may be 
physiologically and pathophysiologically important in 
the regulation of angiogenesis.  We explored the dis-
tribution ﬂow of iβ2GPI and nβ2GPI in the tumor 
lesion by labeling them with 64Cu,  creating in vivo 
PET imaging probes.  This led to the discovery that 
iβ2GPI and nβ2GPI have similar distributions in the 
tumor lesions.  Our ﬁndings will contribute to the 
further understanding of β2GPI as a potential target 
for the clinical treatment of angiogenesis-related dis-
eases.
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